Relypsa (NASDAQ:RLYP) : The consensus price target for Relypsa (NASDAQ:RLYP) is $30.56 for the short term with a standard deviation of $12.39. The most optimist securities analyst among the 9 who monitor the stock believes that the stock can reach $51, however, the pessimist price target for the company is $9.
Other Equity analysts have also commented on the company shares. In the latest statement by the brokerage house, Wedbush maintains its outlook on Relypsa (NASDAQ:RLYP). The current rating of the shares is Outperform, according to the research report released by the firm. Previously, the company had a rating of Outperform. The brokerage firm maintains the price target from $51 per share to $51 per share. The rating by the firm was issued on June 16, 2016.
Relypsa (NASDAQ:RLYP): stock turned positive on Thursday. Though the stock opened at $17.13, the bulls momentum made the stock top out at $18.1 level for the day. The stock recorded a low of $16.76 and closed the trading day at $18.09, in the green by 5.36%. The total traded volume for the day was 2,104,162. The stock had closed at $17.17 in the previous days trading.
The company shares have dropped -49.68% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $35.97 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $16.85 and the 200 Day Moving Average price is recorded at $18.68. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Torley Helen, director of Relypsa Inc, had unloaded 1,013 shares at an average price of $19.32 in a transaction dated on June 7, 2016. The total value of the transaction was worth $19,571.
Relypsa, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The Companys lead product candidate, Patiromer for Oral Suspension (Patiromer FOS) is for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. Its New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration, or FDA. The Companys NDA is supported by a clinical development program consisting of eight clinical trials: three Phase I trials, four Phase II trials and one two-part Phase III trial conducted under a Special Protocol Assessment, or SPA. The active ingredient is a cross-linked polymeric bead with a calcium containing counterion. The Company has the global royalty-free commercialization rights to Patiromer FOS.